China Pharma Holdings, Inc.: Form 10-Q for the period ended Jun 30, 2022
Filed with the SEC on Aug 11, 2022 and accepted by EDGAR at Aug 11, 2022, 16:05 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2022-04-01 to 2022-06-30 | $1.6m | us-gaap:Revenues |
| Revenue | 6 months2022-01-01 to 2022-06-30 | $3.2m | us-gaap:Revenues |
| Cost of revenue | 3 months2022-04-01 to 2022-06-30 | $1.8m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2022-01-01 to 2022-06-30 | $3.6m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2022-04-01 to 2022-06-30 | −$229.4k | us-gaap:GrossProfit |
| Gross profit | 6 months2022-01-01 to 2022-06-30 | −$398.8k | us-gaap:GrossProfit |
| Research and development | 3 months2022-04-01 to 2022-06-30 | $15.1k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2022-01-01 to 2022-06-30 | $69.1k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2022-04-01 to 2022-06-30 | −$779.6k | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2022-01-01 to 2022-06-30 | −$1.7m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2022-04-01 to 2022-06-30 | $110.0k | us-gaap:InterestExpense |
| Interest expense | 6 months2022-01-01 to 2022-06-30 | $234.5k | us-gaap:InterestExpense |
| Net income | 3 months2022-04-01 to 2022-06-30 | −$888.4k | us-gaap:NetIncomeLoss |
| Net income | 6 months2022-01-01 to 2022-06-30 | −$1.9m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2022-04-01 to 2022-06-30 | −$0.02 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2022-01-01 to 2022-06-30 | −$0.04 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2022-04-01 to 2022-06-30 | −$0.02 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2022-01-01 to 2022-06-30 | −$0.04 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 6 months2022-01-01 to 2022-06-30 | −$1.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2022-01-01 to 2022-06-30 | $176.7k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2022-06-30 | $2.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-06-30 | $6.3m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-06-30 | $17.9m | us-gaap:Assets |
| Current liabilities | At period end2022-06-30 | $8.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-06-30 | $13.9m | us-gaap:Liabilities |
| Shareholders' equity | At period end2022-06-30 | $4.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001213900-22-046859. Last ingested by Listed: Oct 30, 2026, 16:51 ET. Listed shows no prices and gives no investment advice.